U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C31H46O2
Molecular Weight 450.6957
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of PHYTONADIONE, (E)-

SMILES

CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CC1=C(C)C(=O)C2=C(C=CC=C2)C1=O

InChI

InChIKey=MBWXNTAXLNYFJB-NKFFZRIASA-N
InChI=1S/C31H46O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,18-20,22-24H,9-17,21H2,1-6H3/b25-20+/t23-,24-/m1/s1

HIDE SMILES / InChI

Molecular Formula C31H46O2
Molecular Weight 450.6957
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 1
Optical Activity UNSPECIFIED

Phylloquinone is often called vitamin K1 or phytonadione. It is a fat-soluble vitamin that is stable to air and moisture but decomposes in sunlight. It is found naturally in a wide variety of green plants. Phylloquinone is also an antidote for coumatetralyl. Vitamin K is needed for the posttranslational modification of certain proteins, mostly required for blood coagulation. MEPHYTON (Phytonadione tablets) are indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity: anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; hypoprothrombinemia secondary to antibacterial therapy; hypoprothrombinemia secondary to administration of salicylates; hypoprothrombinemia secondary to obstructive jaundice or biliary fistulas but only if bile salts are administered concurrently, since otherwise the oral vitamin K will not be absorbed. MEPHYTON tablets possess the same type and degree of activity as does naturally-occurring vitamin K, which is necessary for the production via the liver of active prothrombin (factor II), proconvertin (factor VII), plasma thromboplastin component (factor IX), and Stuart factor (factor X). The prothrombin test is sensitive to the levels of three of these four factors II, VII, and X. Vitamin K is an essential cofactor for the gamma-carboxylase enzymes, which catalyze the posttranslational gamma-carboxylation of glutamic acid residues in inactive hepatic precursors of coagulation factors II (prothrombin), VII, IX, and X. Gamma-carboxylation converts these inactive precursors into active coagulation factors, which are secreted by hepatocytes into the blood. Supplementing with Phylloquinone results in a relief of vitamin K deficiency symptoms, which include easy bruisability, epistaxis, gastrointestinal bleeding, menorrhagia and hematuria. Oral phytonadione is adequately absorbed from the gastrointestinal tract only if bile salts are present. After absorption, phytonadione is initially concentrated in the liver, but the concentration declines rapidly. Very little vitamin K accumulates in tissues. Little is known about the metabolic fate of vitamin K. Almost no free unmetabolized vitamin K appears in bile or urine. In normal animals and humans, phytonadione is virtually devoid of pharmacodynamic activity. However, in animals and humans deficient in vitamin K, the pharmacological action of vitamin K is related to its normal physiological function; that is, to promote the hepatic biosynthesis of vitamin K-dependent clotting factors. MEPHYTON tablets generally exert their effect within 6 to 10 hours.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P38435
Gene ID: 2677.0
Gene Symbol: GGCX
Target Organism: Homo sapiens (Human)
Target ID: Q9BQB6
Gene ID: 79001.0
Gene Symbol: VKORC1
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
VITAMIN K1

Approved Use

Vitamin K1 Injection is indicated in: (1) anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; (2) prophylaxis and therapy of hemorrhagic disease of the newborn; (3) hypoprothrombinemia due to antibacterial therapy; (3) hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis; (4) other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin K metabolism, e.g., salicylates.

Launch Date

1983
Primary
VITAMIN K1

Approved Use

Vitamin K1 Injection is indicated in: (1) anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; (2) prophylaxis and therapy of hemorrhagic disease of the newborn; (3) hypoprothrombinemia due to antibacterial therapy; (3) hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis; (4) other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin K metabolism, e.g., salicylates.

Launch Date

1983
Preventing
VITAMIN K1

Approved Use

Vitamin K1 Injection is indicated in: (1) anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; (2) prophylaxis and therapy of hemorrhagic disease of the newborn; (3) hypoprothrombinemia due to antibacterial therapy; (3) hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis; (4) other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin K metabolism, e.g., salicylates.

Launch Date

1983
Secondary
MEPHYTON

Approved Use

MEPHYTON is indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity. MEPHYTON tablets are indicated in: anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; hypoprothrombinemia secondary to antibacterial therapy; hypoprothrombinemia secondary to administration of salicylates; hypoprothrombinemia secondary to obstructive jaundice or biliary fistulas but only if bile salts are administered concurrently, since otherwise the oral vitamin K will not be absorbed.

Launch Date

1955
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
32.5 ng/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHYTONADIONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
146 ng × h/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHYTONADIONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4 h
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHYTONADIONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
Doses

Doses

DosePopulationAdverse events​
200 mg 1 times / day steady, intravenous
Highest studied dose
Dose: 200 mg, 1 times / day
Route: intravenous
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 39 years
Health Status: unhealthy
Age Group: 39 years
Sex: M
Sources:
1000 mg single, intravenous
MTD
Dose: 1000 mg
Route: intravenous
Route: single
Dose: 1000 mg
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
PubMed

PubMed

TitleDatePubMed
Absorption of tritiated vitamin K1 in patients with fat malabsorption.
1970 Dec
Femoral neuropathy and anticoagulants.
1972 Jul
Bleeding from self-administration of phenindione: a detailed case study.
1976 Aug
Hematomyelia during anticoagulant therapy.
1985 Nov
Specificity of increased des-gamma-carboxyprothrombin in hepatocellular carcinoma after vitamin K1 injection.
1987 Aug
Anticoagulant-related intracerebral hemorrhage in patients with prosthetic heart valves--report of two cases.
1991 Nov
Pseudoscleroderma secondary to phytomenadione (vitamin K1) injections: Texier's disease.
1996 Feb
The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia.
1997 Nov 1
Interaction between fenofibrate and warfarin.
1998 Jul-Aug
Chemiluminescence analysis of menadione sodium bisulfite and analgin in pharmaceutical preparations and biological fluids.
1999 Dec
The anticoagulant factor, protein S, is produced by cultured human vascular smooth muscle cells and its expression is up-regulated by thrombin.
2000 Mar 15
A conserved motif within the vitamin K-dependent carboxylase gene is widely distributed across animal phyla.
2000 Nov 17
Hepatic failure and encephalopathy attributed to an interaction between acetaminophen and rifampicin.
2001 Apr
Matrix gamma-carboxyglutamic acid protein is a key regulator of PTH-mediated inhibition of mineralization in MC3T3-E1 osteoblast-like cells.
2001 Oct
Vitamin K suppresses lipopolysaccharide-induced inflammation in the rat.
2006 Apr
APOE genotype makes a small contribution to warfarin dose requirements.
2006 Aug
Vitamin K deficiency reduces testosterone production in the testis through down-regulation of the Cyp11a a cholesterol side chain cleavage enzyme in rats.
2006 Oct
Gradual improvement of liver function after administration of ursodeoxycholic acid in an infant with a novel ABCB11 gene mutation with phenotypic continuum between BRIC2 and PFIC2.
2007 Nov
Chronic angiotensin-converting enzyme inhibition up-regulates mouse kidney growth arrest specific-6 protein and the AXL subfamily of receptor tyrosine kinases.
2008 Dec
Effect of cell differentiation for neuroblastoma by vitamin k analogs.
2009 Apr
CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant.
2009 Jun
Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy.
2009 Oct
Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways.
2010 Jul
Matrix Gla protein metabolism in vascular smooth muscle and role in uremic vascular calcification.
2011 Aug 19
Dietary vitamin K alleviates the reduction in testosterone production induced by lipopolysaccharide administration in rat testis.
2011 Jul
Eicosapentaenoic acid reduces warfarin-induced arterial calcification in rats.
2011 Mar
An endogenous vitamin K-dependent mechanism regulates cell proliferation in the brain subventricular stem cell niche.
2012 Apr
Warfarin induces cardiovascular damage in mice.
2013 Nov
FDA-approved drugs and other compounds tested as inhibitors of human glutathione transferase P1-1.
2013 Sep 5
Vitamin K1 in oral solution or tablets: a crossover trial and two randomized controlled trials to compare effects.
2014 Dec
Vitamin K1 exerts antiproliferative effects and induces apoptosis in three differently graded human colon cancer cell lines.
2015
Vitamin K1 distribution following intravenous vitamin K1-fat emulsion administration in rats.
2015 Dec
Vitamin K1 alleviates streptozotocin-induced type 1 diabetes by mitigating free radical stress, as well as inhibiting NF-κB activation and iNOS expression in rat pancreas.
2015 Jan
Effect of vitamin K supplementation on insulin sensitivity: a meta-analysis.
2017
Phylloquinone (Vitamin K1): Occurrence, Biosynthesis and Functions.
2017
Vitamin K plasma levels determination in human health.
2017 May 1
Finding the optimal dose of vitamin K1 to treat vitamin K deficiency and to avoid anaphylactoid reactions.
2017 Oct
Patents

Sample Use Guides

Prophylaxis of Hemorrhagic Disease of the Newborn: A single intramuscular dose of (E)-phytonadione (Vitamin K1 Injection) 0.5 to 1 mg within one hour of birth is recommended. Treatment of Hemorrhagic Disease of the Newborn: 1 mg should be given either subcutaneously or intramuscularly. Anticoagulant-Induced Prothrombin Deficiency in Adults: the dose of 2.5 mg to 10 mg or up to 25 mg is recommended. Hypoprothrombinemia due to other causes: a dosage of 2.5 to 25 mg or more (rarely up to 50 mg) is recommended.
Route of Administration: Other
In Vitro Use Guide
Curator's Comment: Vitamin K1 (VK1) inhibited the expression of heat-shock protein 72 (Hsp72) but did not affect the constitutive expression of Hsc70 or calnexin in vitro and in vivo. VK1 and VK2 sensitized A549 cells to heat-shock induced cell death, while the compounds alone had no effect on cell viability. The suppression of Hsp72 was apparently at the protein level because the mRNA expression of Hsp72 was unchanged.
Human lymphocytes were incubated with (E)-phytonadione at a dose of 1 uM. At this concentration (E)-phytonadione significantly increased Sister Chromatid Exchange.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:10:46 GMT 2025
Edited
by admin
on Mon Mar 31 18:10:46 GMT 2025
Record UNII
S5Z3U87QHF
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NSC-270681
Preferred Name English
PHYTONADIONE, (E)-
Common Name English
SYNTHEX P
Common Name English
PHYTONADIONE [JAN]
Common Name English
PHYLLOQUINONE, (E)-
Common Name English
PHYLLOQUINONE E-FORM [MI]
Common Name English
PHYTOMENADIONE, (E)-
Common Name English
MONODION
Common Name English
2-METHYL-3-((7R,11R,E)-3,7,11,15-TETRAMETHYLHEXADEC-2-EN-1-YL)NAPHTHALENE-1,4-DIONE
Systematic Name English
2-METHYL-3-((2E,7R,11R)-3,7,11,15-TETRAMETHYL-2-HEXADECENYL)-1,4-NAPHTHALENEDIONE
Systematic Name English
Code System Code Type Description
WHO INTERNATIONAL PHARMACOPEIA
PHYTONADIONE, (E)-
Created by admin on Mon Mar 31 18:10:46 GMT 2025 , Edited by admin on Mon Mar 31 18:10:46 GMT 2025
PRIMARY Description: A clear, yellow to amber-coloured, very viscous liquid; odourless or almost odourless. Miscibility: Practically immiscible with water; sparingly miscible with ethanol (~750 g/l) TS; freely miscible with chloroform R and ether R. Category: Anticoagulant.Storage: Phytomenadione should be kept in a tightly closed container, protected from light. Definition: Phytomenadione contains not less than 97.0% and not more than 102.0% of C31H46O2.
NSC
270681
Created by admin on Mon Mar 31 18:10:46 GMT 2025 , Edited by admin on Mon Mar 31 18:10:46 GMT 2025
PRIMARY
PUBCHEM
5284607
Created by admin on Mon Mar 31 18:10:46 GMT 2025 , Edited by admin on Mon Mar 31 18:10:46 GMT 2025
PRIMARY
FDA UNII
S5Z3U87QHF
Created by admin on Mon Mar 31 18:10:46 GMT 2025 , Edited by admin on Mon Mar 31 18:10:46 GMT 2025
PRIMARY
MERCK INDEX
m8762
Created by admin on Mon Mar 31 18:10:46 GMT 2025 , Edited by admin on Mon Mar 31 18:10:46 GMT 2025
PRIMARY Merck Index
HSDB
3162
Created by admin on Mon Mar 31 18:10:46 GMT 2025 , Edited by admin on Mon Mar 31 18:10:46 GMT 2025
PRIMARY
CAS
84-80-0
Created by admin on Mon Mar 31 18:10:46 GMT 2025 , Edited by admin on Mon Mar 31 18:10:46 GMT 2025
PRIMARY
ECHA (EC/EINECS)
201-564-2
Created by admin on Mon Mar 31 18:10:46 GMT 2025 , Edited by admin on Mon Mar 31 18:10:46 GMT 2025
PRIMARY
WIKIPEDIA
Phytomenadione
Created by admin on Mon Mar 31 18:10:46 GMT 2025 , Edited by admin on Mon Mar 31 18:10:46 GMT 2025
PRIMARY
DRUG BANK
DB01022
Created by admin on Mon Mar 31 18:10:46 GMT 2025 , Edited by admin on Mon Mar 31 18:10:46 GMT 2025
PRIMARY
EPA CompTox
DTXSID8023472
Created by admin on Mon Mar 31 18:10:46 GMT 2025 , Edited by admin on Mon Mar 31 18:10:46 GMT 2025
PRIMARY